

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5614593

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CHUAN-CHU CHOU	09/06/2018
	YAFENG ZHANG	08/21/2018
	SHU WU	08/28/2018
	ZHENYU LIU	10/25/2018
	ZHONGDAO LI	10/10/2018
	FANGLIANG ZHANG	10/25/2018
RECEIVING PARTY DATA		
Name:	NANJING LEGEND BIOTECH CO., LTD.	
Street Address:	NO. 6 BUILDING OF NANJING LIFE SCIENCE TOWN	
Internal Address:	NO. 568 LONGMIAN AVENUE JIANGNING DISTRICT	
City:	NANJING CITY, JIANGSU	
State/Country:	CHINA	
Postal Code:	211100	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16319224
CORRESPONDENCE DATA		
Fax Number:	(650)494-0792	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(650) 813-5736	
Email:	mchacon@mofo.com	
Correspondent Name:	JIAN XIAO	
Address Line 1:	MORRISON & FOERSTER LLP - PA	
Address Line 2:	755 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1018	
ATTORNEY DOCKET NUMBER:	76142-20002.00	
NAME OF SUBMITTER:	JIAN XIAO	
SIGNATURE:	/Jian Xiao/	
DATE SIGNED:	07/11/2019	

PATENT

Total Attachments: 2

source=76142-20002.00 Assignment - Inventors to Nanjing Legend Biotech Co. Ltd#page1.tif

source=76142-20002.00 Assignment - Inventors to Nanjing Legend Biotech Co. Ltd#page2.tif

PATENT ASSIGNMENT

WHEREAS, the undersigned,

1. Chuan-cha Chou
New Jersey 07090
United States of America

2. Yafeng Zhang
Nanjing city
Jiangsu 211100, China

3. Shu Wu
Nanjing city
Jiangsu 211100, China

4. Zhenyu Liu
Nanjing city
Jiangsu 211100, China

5. Zhongdao Li
Nanjing city
Jiangsu 211100, China

6. Fangfang Zhang
Nanjing city
Jiangsu 211100, China

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

Multispecific Antigen Binding Proteins and Methods of use thereof

for which the following application has been filed:

International Application No. PCT/CN2016/090703, Filed on July 20, 2016

International Application No. PCT/CN2017/093644, Filed on July 20, 2017

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Nanjing Legend Biotech Co., Ltd., a corporation incorporated in China, having a place of business at No. 6 Building of Nanjing Life Science Town, No. 568 Longmian Avenue, Jiangning District, Nanjing city, Jiangsu 211100, China, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) hereinafter collectively referred to as "Inventors"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions, (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Applications; (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed in the United States, all foreign countries or jurisdictions and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest therein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions, and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:


PATENT ASSIGNMENT

Date:

9/6/2018

Signature:

Chun-chu Chou




Date:

8/31/2018

Signature:

Yafeng Zhang




Date:

8/21/2018

Signature:

Shu Wu




Date:

10/10/2018

Signature:

Zhenyu Liu




Date:

10/10/2018

Signature:

Zhongdao Li




Date:

10/25/2018

Signature:

Fangfang Zhang



RECEIVED AND AGREED TO BY ASSIGNEE:

Nanjing Legend Biotech Co., Ltd.

Date:

10/26/2018

Signature:

